Malaysian Genomics Resource (0155) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.005x

Based on the latest financial reports, Malaysian Genomics Resource (0155) has a cash flow conversion efficiency ratio of 0.005x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RM98.00K ≈ $24.60K USD) by net assets (RM18.28 Million ≈ $4.59 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Malaysian Genomics Resource (0155) balance sheet quality index to measure how much of total assets are equity-financed.

Malaysian Genomics Resource - Cash Flow Conversion Efficiency Trend (2015–2026)

This chart illustrates how Malaysian Genomics Resource's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 0155 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Malaysian Genomics Resource Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Malaysian Genomics Resource ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Patria Private Equity Trust LSE:PPET	-0.001x
Ainos Inc NASDAQ:AIMD	-0.113x
Star Diamond Corp TO:DIAM	-0.102x
INNEOVA Holdings Limited NASDAQ:INEO	0.954x
M.P.Evans Group LSE:MPE	0.128x
Hays plc LSE:HAS	0.122x
Admiralty Resources NL AU:ADY	0.000x
AirIQ Inc V:IQ	0.049x

Annual Cash Flow Conversion Efficiency for Malaysian Genomics Resource (2015–2026)

The table below shows the annual cash flow conversion efficiency of Malaysian Genomics Resource from 2015 to 2026. For the full company profile with market capitalisation and key ratios, see Malaysian Genomics Resource market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2026-06-30	RM14.78 Million ≈ $3.71 Million	RM1.10 Million ≈ $277.42K	0.075x	+282.15%
2025-06-30	RM18.16 Million ≈ $4.56 Million	RM-744.97K ≈ $-187.04K	-0.041x	+96.33%
2024-06-30	RM22.35 Million ≈ $5.61 Million	RM-24.97 Million ≈ $-6.27 Million	-1.117x	-35.64%
2023-06-30	RM26.79 Million ≈ $6.73 Million	RM-22.07 Million ≈ $-5.54 Million	-0.824x	-53707.58%
2022-06-30	RM37.05 Million ≈ $9.30 Million	RM56.92K ≈ $14.29K	0.002x	+101.05%
2021-06-30	RM17.93 Million ≈ $4.50 Million	RM-2.64 Million ≈ $-661.90K	-0.147x	-112.93%
2020-06-30	RM10.26 Million ≈ $2.58 Million	RM11.67 Million ≈ $2.93 Million	1.137x	+2735.15%
2019-06-30	RM15.93 Million ≈ $4.00 Million	RM-687.64K ≈ $-172.64K	-0.043x	+86.54%
2018-06-30	RM19.77 Million ≈ $4.96 Million	RM-6.34 Million ≈ $-1.59 Million	-0.321x	-312.09%
2017-06-30	RM24.30 Million ≈ $6.10 Million	RM3.67 Million ≈ $922.57K	0.151x	-20.39%
2016-06-30	RM19.39 Million ≈ $4.87 Million	RM3.68 Million ≈ $924.53K	0.190x	+746.88%
2015-06-30	RM17.65 Million ≈ $4.43 Million	RM395.83K ≈ $99.38K	0.022x	--

About Malaysian Genomics Resource

KLSE:0155 Malaysia Diagnostics & Research

Market Cap

$11.18 Million

RM44.52 Million MYR

Market Cap Rank

#26767 Global

#821 in Malaysia

Share Price

RM0.30

Change (1 day)

+1.72%

52-Week Range

RM0.17 - RM0.30

All Time High

RM2.72